• About Marc C. Smaldone, MD

    Dr. Smaldone is an attending surgeon specializing in urologic oncology at Fox Chase Cancer Center.


    Can doctors prevent overtreatment for prostate cancer patients?

    by  • August 2, 2013 • Active Surveillance, Cancer Staging, Prostate Cancer

    In a recent article in the Journal of the American Medical Association, entitled, “Overdiagnosis and Overtreatment in Cancer An Opportunity for Improvement,” a group of experts discussed the findings from a National Cancer Institute working group designed to improve the current approach to cancer screening and prevention1. Among their recommendations included a motion to...

    Read more →

    Protons versus Photons for the Treatment of Prostate Cancer

    by  • June 14, 2013 • Prostate Cancer

    The management of clinically localized prostate cancer, or cancer that has not spread beyond the prostate gland, is complex. There are a number of treatment options, ranging from close observation with frequent reassessment (active surveillance), surgery, and radiation therapy. While each form of active treatment can be effective, all can cause side effects that...

    Read more →

    The Role of PSA Velocity in the Early Detection of Prostate Cancer

    by  • February 6, 2013 • Cancer Screening, Prostate Cancer, Uncategorized

    The controversial decision by the United States Preventive Services Task Force (USPSTF) recommending against screening for prostate cancer with the prostate specific antigen (PSA) test has resulted in confusion for patients and physicians alike. Historically, urologist referral to discuss the need for a diagnostic prostate biopsy has been based on the use of threshold...

    Read more →

    Has Robotic Cystectomy Reached the Mainstream?

    by  • January 17, 2013 • Bladder Cancer, Uncategorized

    The current gold standard therapy for muscle invasive bladder cancer consists of a combination of systemic chemotherapy and surgical resection. Radical cystoprostatectomy (removal of the bladder and prostate) in men, and anterior pelvic exenteration (removal of the bladder, uterus, ovaries and a portion of the vagina) in women, in combination with removal of the...

    Read more →

    Prostate Cancer: Is PSA Screening Worth the Trouble?

    by  • November 14, 2012 • Cancer Screening, Prostate Cancer, Uncategorized

    In May 2012, the United States Preventive Services Task Force finalized a controversial draft statement recommending against routine prostate specific antigen (PSA)-based screening for prostate cancer. Praised by some, and harshly criticized by others, these revisions have sparked debate regarding the benefits of screening and early detection of prostate cancer, leaving men confused and...

    Read more →